Gilead (GILD) nears up to USD 2bln deal for autoimmune biotech Ouro Medicines, according to FT

Gilead's potential acquisition of Ouro Medicines for up to USD 2 billion marks a significant move in the biotech space, particularly in the autoimmune sector. This deal could bolster Gilead's pipeline and may indicate a strategic shift towards expanding its therapeutic offerings, which is crucial given the competitive landscape. Market sentiment may react favorably if investors view the acquisition as accretive and synergistic with Gilead's existing portfolio.